Following the U.S. International Trade Commission’s (ITC) decision that it will not pursue an investigation requested by Amarin Pharma, Inc. (U.S. office in New Jersey) and Amarin Pharmaceuticals Ireland Ltd. concerning concentrated EPA omega-3 fish oil supplements, the Council for Responsible Nutrition (CRN) issued the following statement on October 30:

Statement from Steve Mister, president & CEO, CRN:

“CRN extends its appreciation to ITC for its decision to reject a complaint filed by Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Ltd. against omega-3 companies. In doing so, ITC recognizes that, under the Food, Drug & Cosmetic Act, FDA [U.S. Food and Drug Administration] has exclusive authority to make the determination requested by Amarin—and, for that, we are grateful. This decision is a victory not only for legitimate manufacturers that sell legal fish oil supplements, but for consumers depending on accessible, affordable products that benefit their health and well-being.

“We graciously acknowledge those who worked parallel to CRN in advising ITC toward this crucial decision. Individual companies, industry trade associations, and bipartisan voices from Capitol Hill maintained a strong, united presence on the front lines of opposition efforts, and we are pleased to see the proper jurisdiction of FDA respected and maintained.”

For more information, visit www.crnusa.org.